Cannabis Use Disorder Treatment Market: Global Growth

The cannabis use disorder (CUD) treatment market is on the brink of rapid expansion, reflecting a global trend towards recognising the health implications linked with cannabis dependency. Accelerated by increasing cannabis consumption, legislative movements, and a heightened awareness of usage-related risks, the market is forecast to grow from a valuation of USD 1.7 billion in 2025 to USD 2.7 billion by 2035, with a CAGR of 4.7% during the period.

This surge underscores the growing need for effective treatment interventions in response to rising dependency cases. Below, we’ll explore the driving forces behind this expansion and examine how different regions and innovations are shaping the market’s trajectory.

Impact of Rising Cannabis Use Cases

The increasing legalisation of cannabis across various markets, such as North America, Europe, and parts of Asia, has brought a profound shift in consumption rates. While cannabis is often lauded for its recreational and medicinal benefits, the uptick in usage has contributed to a parallel rise in dependency cases and cannabis-related health concerns, including cognitive impairment and mental health disorders like anxiety and depression.

Healthcare systems globally are ramping up investments in interventions to address these concerns. Scientific research highlights that long-term cannabis use can lead to dependency and withdrawal symptoms, which have sparked efforts to develop both behavioural and pharmacological treatments.

Treatment Innovations to Address Rising Dependency

Many medical advancements are occurring in the realm of cannabis use disorder treatment. Cognitive behavioural therapy (CBT) is the most widely practised intervention, offering personalised strategies to help users manage dependency and reduce relapse rates. Further encouraging developments are on the horizon as pharmacological treatments, including N-acetyl cysteine and cannabidiol (CBD)-based therapies, undergo clinical trials to enhance effectiveness.

This blend of behavioural and pharmacological approaches reflects the industry’s commitment to improving treatment outcomes through advanced interventions.

Digital Therapeutics and Telemedicine’s Role

The digitisation of healthcare is proving instrumental in modernising CUD treatment. Telemedicine platforms and digital therapeutics (DTx) are enabling patients to access therapy from the comfort of their homes, eliminating the stigma often associated with addiction treatment while bridging geographical gaps. These technologies have expanded access to addiction counselling in regions where traditional services may be limited.

Furthermore, embedding CUD treatment into broader mental health services has yielded significant patient outcomes. By addressing co-occurring conditions alongside cannabis dependency, such hybrid approaches have gained traction, particularly in underserved areas.

Key Regional Perspectives

Understanding regional dynamics is vital to appreciating the global outlook of the CUD treatment market. Below is an analysis of key regions driving and responding to market trends:

United States

The United States leads the global market, accounting for the largest share due to widespread cannabis legalisation and a substantial consumer base. Institutions like the National Institute on Drug Abuse (NIDA) are intensifying efforts to develop innovative treatments, driven by government funding and public-private partnerships. Furthermore, insurance coverage for CUD treatment is helping increase affordability and access.

CAGR (2025–2035): 5.1%

United Kingdom

The UK has seen a rise in young adults seeking help for cannabis dependency. The NHS, alongside private treatment facilities, is expanding its offerings to tackle these challenges. Cognitive-behavioural therapy and contingency management programs are particularly favoured here. Research into drug-assisted treatments also holds potential for future growth.

CAGR (2025–2035): 4.5%

European Union

Countries such as Germany, France, and the Netherlands are making strides in addressing CUD through government-backed mental health infrastructure and enhanced recovery clinics. Pharmaceutical players are also investing in treatments aimed at addressing cannabis withdrawal symptoms, gaining significant traction in the region.

CAGR (2025–2035): 4.8%

Japan

Despite restrictive cannabis laws, growing international conversations around mental health are influencing a slow shift in public perception. Early-stage treatment frameworks are being trialed, with academic research focused on non-addictive neuropharmacological solutions.

CAGR (2025–2035): 3.9%

South Korea

South Korea’s strict anti-cannabis policies leave limited space for market growth. However, international influences and increasing awareness of cannabis-related issues, particularly among returning travelers, are generating initial steps towards addressing cannabis dependence.

CAGR (2025–2035): 4.2%

Trends Driving Market Growth

Several trends and drivers are catalysing the development of the cannabis use disorder treatment market:

Legalisation Efforts: Expanded recreational and medicinal cannabis legalisation in key economies has raised the number of cannabis users requiring treatment solutions.
Research Investments: Increased funding into pharmacological therapies and behavioural innovations enhances treatment effectiveness, diversifying available options.
Insurance Coverage: The inclusion of addiction treatment in health plans globally reduces financial barriers and improves accessibility.
Integrated Programs: Combining mental health services with addiction treatments addresses co-occurring conditions effectively, reducing relapse rates.

Competitive Landscape and Market Innovations

The competitive landscape of the CUD treatment market continues to evolve substantially. Leading companies, such as Cipla Limited, Orexo AB, and Dr. Reddy’s Laboratories, have embraced innovations ranging from FDA-approved pharmacological advancements to digital platforms for remote care. Strategic partnerships and clinical trials are being sought to refine treatment solutions further, with digital therapeutics playing an increasingly pivotal role.